CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel...
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...
WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing...
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02,...
Ronnie Miller, President and CEO of Roche Canada from 2000-2022 retiring after 43 years of leadership service in the Pharmaceutical...
Intra-Articular Injection Strategy Shows Efficacy Across Multiple Clinical Endpoints and Favorable Safety Profile After 12 Weeks of Therapy Data...
MENLO PARK, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on...
VANCOUVER, British Columbia, March 02, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the “Company” or “Simply Better Brands” or...
NVIDIA platform streamlines adoption, accelerates deployment of iCAD’s solutions in virtualized data centersNASHUA, N.H., March 02, 2022 (GLOBE NEWSWIRE) --...
MIAMI, March 02, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular...
NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing...
BILLERICA, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced that it was suspending all distribution operations to...
Featured Image for Owkin Featured Image for OwkinNEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Owkin appointed Professor Vassili Soumelis...
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics First-in-class peptidomimetic with distinct MoA...
– In the initial clinical data from low-dose cohort of the ongoing trial, we observed that LX1001 expressed the protective...
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic CardiomyopathySOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated...
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing...
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)FORT COLLINS, Colo., March...
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on...
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for...
